

RESEARCH

Open Access



Disruption of the Golgi protein *Otg1* gene causes defective hormone secretion and aberrant glucose homeostasis in mice

Guangxue Wang^{1†}, Rongbo Li^{1†}, Ying Yang^{1†}, Liang Cai¹, Sheng Ding², Tian Xu^{1,2}, Min Han^{1,3} and Xiaohui Wu^{1*} 

Abstract

Background: Concerted hormone secretion is essential for glucose homeostasis and growth. The oocyte testis gene 1 (*Otg1*) has limited information in mammals before. Human OTG1 has been identified as an antigen associated with cutaneous T cell lymphoma, while worm *Otg1* is recently reported to be a vesicle trafficking regulator in neurons. To understand the physiological role of *Otg1* and its potential relation to hormone secretion, we characterized a mutation caused by the *piggyBac* transposon (*PB*) insertion in mice.

Results: Oocyte testis gene 1 encodes a Golgi localized protein that is expressed with a broad tissue distribution in mice. The *PB* insertion effectively blocks *Otg1* expression, which results in postnatal lethality, growth retardation, hypoglycemia and improved insulin sensitivity in mice. *Otg1* mutants exhibit decreased levels of insulin, leptin and growth hormone in the circulation and reduced hepatic IGF-1 expression. Decreased expression of *Otg1* in pituitary GH3 cells causes reduced growth hormone expression and secretion, as well as the traffic of the VSVG protein marker.

Conclusions: Our data support the hypothesis that *Otg1* impacts hormone secretion by regulating vesicle trafficking. These results revealed a previously unknown and important role of *Otg1* in hormone secretion and glucose homeostasis in mammals.

Keywords: *Otg1*, Hypoglycemia, Hypoinsulinemia, Vesicle trafficking

Background

Glucose is the key source for energy production in mammals. Under normal physiological conditions, the blood glucose level is well regulated by concerted actions of the pancreas, liver, adipose tissue, muscle and brain [1, 2]. Abnormal glucose homeostasis would result in hyperglycemia or hypoglycemia. Hyperglycemia is the characteristic condition of diabetes, which has becoming a rapidly growing health threat in modern society [3]. Chronic

hyperglycemia causes glycation of proteins or lipids, which causes many of the long-term complications in diabetic patients [4]. In contrast, since glucose supplies almost all the energy for the brain, hypoglycemia may quickly cause loss of consciousness or even death.

Peptide hormones such as insulin, glucagon, growth hormone and IGF-1 play critical roles in regulating glucose homeostasis [5–9]. Being expressed, peptide hormones are packaged in vesicles at the trans-Golgi network (TGN), transported on microtubules toward the plasma membrane and loaded onto an actin/myosin system for distal transport through the actin cortex to just below the plasma membrane. After tethered there, a subpopulation of vesicles are docked and primed to become the readily-releasable pools [10, 11]. Upon stimulation, these vesicles in the readily-releasable pool would immediately fuse to the plasma membrane to release the

*Correspondence: xiaohui_wu@fudan.edu.cn

[†]Guangxue Wang, Rongbo Li and Ying Yang contributed equally to this work

¹ State Key Laboratory of Genetic Engineering and National Center for International Research of Development and Disease, Institute of Developmental Biology and Molecular Medicine, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200433, China

Full list of author information is available at the end of the article

contents. This process is essential for activity-dependent hormone secretion to mediate various endocrinological functions. Despite of many identified proteins involved in vesicle budding, trafficking, tethering/docking and cargo secretion, the molecular mechanisms and molecules participating peptide hormone secretion remain to be explored.

The oocyte-testis gene 1 (*Otg1*) was originally identified in the RIKEN Mouse Gene Encyclopedia Project [12]. The full-length transcript has 16 exons that encode a 917-amino acid peptide. The OTG1 protein has several coiled-coil domains that occupy almost half of the peptide. Other than these, no functional motifs have been predicted in OTG1 [13]. The human homologue of *Otg1* encodes the protein that has been recognized as a cutaneous T-cell lymphoma (CTCL) associated antigen [14]. Recently, the *C. elegans* homologue of *Otg1* has been reported as a vesicle trafficking regulator in neurons [15]. Here we report that mouse *Otg1* encodes a protein with prominent Golgi localization. Loss of *Otg1* results in postnatal lethality, aberrant glucose homeostasis and defective hormone secretion in mice. These results revealed an unknown role of *Otg1* in participating hormone secretion and metabolic regulation in mammals.

Results

Disruption of *Otg1* results in postnatal lethality and growth retardation in mice

We identified an *Otg1* mutant in a screen for mice bearing metabolic defects [16]. The mutant carries a *piggyBac* transposon (*PB*) insertion in the eighth exon of *Otg1* (*Otg1^{PB}*) that effectively disrupts gene expression (Fig. 1a). In wild-type animals, *Otg1* proteins can be readily detected in various organs such as the brain, heart, lung, stomach, liver, kidney, pancreas and gut. In tissues from homozygous mutants, *Otg1* expression is no longer detectable (Fig. 1b). Similar changes were also observed by immunofluorescence staining in pancreatic cells and embryonic fibroblasts (MEFs) with different genotypes (Fig. 1c and Additional file 1: Figure S1). Similar as that of the *C. elegans* homologue, immunofluorescence staining in wild-type pancreatic cells and MEFs revealed co-localization of OTG1 proteins with the Golgi compartment marker Giantin, confirming a Golgi localization of OTG1 in mice (Fig. 1c) [15, 17].

Oocyte testis gene 1^{PB/PB} animals were born in consistent with a Mendelian pattern of inheritance (Additional file 2: Table S1). However, 46.5 % (53/114) homozygous *Otg1* mutants could not survive throughout the first day after birth (P1), while others gradually died within the next 30 days. In contrast, 96.4 % (108/112) wild-type and 94.2 % (196/208) heterozygous littermates kept alive at the age of one month (Fig. 2a). The external morphology

of mutants died at P1 was apparently normal. In contrast, the most obvious morphological changes of other dead mutants were their small sizes (Fig. 2c). Further analysis showed that *Otg1^{PB/PB}* individuals had comparable body weight with their littermates both at the end of fetal development (embryonic day 18.5, Additional file 3: Figure S2C) and at birth (Fig. 2b). Soon after that, the survivors suffered from severe growth retardation. The body weight of *Otg1^{PB/PB}* mice increased much slower than that of the wild-type and heterozygous littermates. In fact, homozygous *Otg1* mutants always exhibit lipohypotrophy and usually died before the body weight reaches 5 grams (Fig. 2b, d).

Otg1 mutation leads to impaired glucose homeostasis

We then explored pathophysiological alterations that may lead to postnatal lethality and growth retardation in *Otg1^{PB/PB}* mice. Alcian blue-alizarin red staining revealed normal skeleton structures in *Otg1^{PB/PB}* mutants (Additional file 3: Figure S2A). This result, along with the normal body weight of newborn animals, suggests that severe embryonic developmental defects, such as abnormal pattern formation, shall not be accounted for postnatal lethality and growth retardation. We often observed milk in the stomach of *Otg1^{PB/PB}* pups, suggesting that feeding failure is unlikely the reason for growth retardation and lethality (Additional file 3: Figure S2B).

Given the critical role of glucose in supporting growth, we examined glucose homeostasis in mutant mice. We observed progressively developed hypoglycemia in *Otg1* mutants. The blood glucose level in free-fed *Otg1^{PB/PB}* mice was similar as that in the wild-type and heterozygous littermates at birth, then decreased to approximately 25 % below normal within two days and further dropped to 58 % of that in the wild-type at the age of 11 days (P11) (Fig. 3a, b). Fasted blood glucose levels of P11 *Otg1^{PB/PB}* mice were only 47 % of that in the wild-type mice. In intraperitoneal glucose tolerance test (IPGTT), the blood glucose level of P11 *Otg1^{PB/PB}* mice changed with the same tendency as that of the wild-type or heterozygous mice, but kept to be approximately 60 % lower at each time point (Fig. 3c). In addition to hypoglycemia, we recorded extremely low level of serum insulin and elevated insulin sensitivity in the mutants. Compared with 0.66 and 0.57 ng/ml of serum insulin detected in wild-type and heterozygous littermates, respectively, ELISA analysis revealed an average insulin concentration of 0.02 ng/ml in P11 homozygotes (Fig. 3d). In the insulin tolerance test (ITT), the blood glucose level of P11 *Otg1^{PB/PB}* mice dropped more rapidly than that of the wild-type and heterozygous littermates. In fact, it decreased to a level too low to be detected within 30 min (Fig. 3e). Finally, we observed hypoleptinemia in *Otg1*




Fig. 1 A PB insertion effectively abolished *Otg1* expression. **a** Schematic representation of the genomic sequence flanking *PB* insertion site in *Otg1*. White box: exon. **b** Western blot did not detect OTG1 expression in either E13.5 *Otg1*^{PB/PB} embryos or tissues of P1 *Otg1*^{PB/PB} mice. **c** Immunofluorescence staining showed co-localization of OTG1 protein and Giantin in both pancreatic tissues of MEFs from wild-type mice

mutants. Consistent with lipodystrophy, *Otg1*^{PB/PB} mice had circulating leptin below detectable level (<0.2 ng/ml) at P11 (Fig. 3f).

Growth retardation, hypoinsulinemia, hypoglycemia and increased insulin sensitivity have been reported in mice with defective growth hormone receptors (GHRs)

[7, 9]. This raises the possibility that growth hormone (GH) signaling is aberrant in *Otg1*^{PB/PB} mice. We measured the expressions of GH and its downstream mediator IGF-1. Compared with those of the wild-type littermates, ELISA revealed approximately 35 % reduction of serum GH levels in P11 *Otg1*^{PB/PB} mice, while real-time RT-PCR




Fig. 2 Postnatal lethality and growth retardation in *Otg1* mutant mice. **a** Survival curves of *Otg1*^{PB/PB} (n = 114), *Otg1*^{PB/+} (n = 208) and wild-type (n = 114) littermates. **b** Body weight curves of *Otg1*^{PB/PB} (n = 25), *Otg1*^{PB/+} (n = 38) and wild-type (n = 18) littermates. **c** Representative image showing the body size difference between an *Otg1*^{PB/PB} and a wild-type mouse at P11. **d** Representative image of the hypodermis histological section of P4 *Otg1*^{PB/PB} and *Otg1*^{+/+} mice, showing severe lipodystrophy of the mutant

detected 50 and 87 % decrease of hepatic *IGF-1* expression in P1 and P11 mutants, respectively (Fig. 3g, h). Taken together, the results above suggest that disruption of *Otg1* leads to impaired glucose homeostasis in mice.

Otg1 mutation leads to aberrant vesicle trafficking

Given its Golgi localization and the reported role of the *C. elegans* homologue in neurons [15], *Otg1* is likely to be involved in vesicle trafficking, a process that is critical for protein hormone secretion in mammals. Consistent with this predicted role, we found *Otg1*^{PB/PB} mice had islet cells 48 % of the sizes of their wild-type littermates (Fig. 4a, b). This is likely the consequence of defective vesicle trafficking rather than the result of smaller body size, since *Otg1*^{PB/PB} hepatocytes are of similar sizes as those of the *Otg1*^{+/PB} animals (Additional file 4: Figure S3). Electron microscopy also revealed a greatly reduced number of insulin granules in the cytoplasm of mutant β cells (Fig. 4c). To mask the possible effect on insulin secretion from reduced GH signaling in vivo, we isolated islets from newborn mutants and examined their response to glucose challenge by measuring secreted

insulin in the culture medium. There was no significant difference between *Otg1*^{PB/PB} and the wild-type islets when they were provided with basal level (3 mM) of glucose. However, when challenged by 25 mM of glucose for 1 h, the insulin concentration in the culture medium of *Otg1*^{PB/PB} islets was only 25 % of that of the wild-type islets (Fig. 4d). Altogether, these results suggest that the smaller islet cells are likely the result of defective vesicle trafficking caused by the *Otg1* mutation.

The role of *Otg1* in hormone secretion was further confirmed in rat pituitary GH3 somatolactotropes, a popular model to study GH secretion [18]. We first knocked down *Otg1* expression with small hairpin RNAs (shRNAs), then measured GH released into the medium within a period of two hours. Compared with cells transfected with scramble shRNAs, shRNA-1 and shRNA-2 transfected cells produced 55 and 58 % less *Otg1* proteins, respectively (Fig. 4e). As expected, shRNA-1 transfection resulted in a reduction of GH content and secretion by 52 and 58 %, respectively, while shRNA-2 transfection resulted in a reduction of GH content and secretion by 43 and 56 %, respectively (Fig. 4f, g).





Fig. 3 Impaired glucose homeostasis in *Otg1* mutant mice. **a** Blood glucose levels of newborn *Otg1^{PB/PB}* (P1: n = 13; P2: n = 10), *Otg1^{PB/+}* (P1: n = 30; P2: n = 30) and wild-type (P1: n = 16; P2: n = 11) littermates. **b** Blood glucose levels of free fed or 2-hour starved *Otg1^{PB/PB}* (n = 10), *Otg1^{PB/+}* (n = 19) and wild-type (n = 10) littermates at P11. **c** Intraperitoneal glucose tolerance test (IPGTT) performance of *Otg1^{PB/PB}* (n = 4), *Otg1^{PB/+}* (n = 6) and wild-type (n = 3) littermates at P11. **d** Serum insulin levels of *Otg1^{PB/PB}* (n = 10), *Otg1^{PB/+}* (n = 19) and wild-type (n = 10) littermates at P11. **e** Insulin tolerance test (ITT) results of *Otg1^{PB/PB}* (n = 4), *Otg1^{PB/+}* (n = 8) and wild-type (n = 5) littermates at P11. **f** Serum leptin levels of *Otg1^{PB/PB}* (n = 7), *Otg1^{PB/+}* (n = 5) and wild-type (n = 4) littermates. **g** Serum growth hormone levels of *Otg1^{PB/PB}* (n = 17) and wild-type (n = 15) littermates. **h** Relative IGF-1 expression in *Otg1^{PB/PB}* (P1: n = 5; P2: n = 4) and wild-type (P1: n = 3; P11: n = 5) littermates. *p < 0.05, **p < 0.01, ***p < 0.005




Decreased hormone secretion in both mouse islet and rat GH3 suggested a critical role of *Otg1* in hormone secretion in mammals. To monitor the effect of *Otg1* on intracellular transport, we used VSVG-mEmerald, a fluorescent reporter that translocates from endoplasmic reticulum to the plasma membrane via the Golgi apparatus at 37 °C [19]. Live-cell imaging showed that the transportation of VSVG-mEmerald was significantly blocked in *Otg1* knockdown GH3 cells (Additional file 5: Video S1 and Additional file 6: Video S2). The average transport speed of VSVG-mEmerald vesicles (n = 110) was 0.068 $\mu\text{m}/\text{sec}$ in *shRNA-1* treated cells, but 0.186 $\mu\text{m}/\text{sec}$ in scramble shRNA treated cells (Fig. 5a). Standard deviations of the transport speed in each *shRNA-1* treated cell (n = 11) were also decreased

(Fig. 5b and Additional file 7: Figure S4). These results suggest that *Otg1* is required for vesicle trafficking in mammalian cells.

Discussion

In the present study, we have shown that *Otg1* encodes a Golgi protein that is required for normal vesicle trafficking in mammalian cells. Disruption of *Otg1* results in growth retardation and postnatal lethality in mice. Various abnormalities related to glucose homeostasis, such as hypoinsulinemia, hypoglycemia, increased insulin sensitivity, decreased serum growth hormone level and reduced hepatic IGF-1 expression, could be observed in mutant animals before death. These results revealed an unknown function *Otg1* in metabolic regulation.



Oocyte testis gene 1 is ubiquitously expressed with a prominent Golgi localization. Almost half of the peptide sequence is occupied by coiled-coil regions with short interruptions. OTG1 is a conserved protein during evolution and the human homologue has been identified as a tumor antigen. These features are reminiscent of those of

the golgin coiled-coil proteins, which are known as membrane and cytoskeleton tethers [20, 21]. Although the C-terminus of OTG1 lacks a transmembrane or a small GTPase interacting signal, which are usually presented in a typical goglin, OTG1 may still be involved in similar intracellular activities by serving as molecular partners

of typical golgins. Under this scenario, OTG1 may be involved not only in capturing incoming vesicles, but also in providing specificity to the tethering step.

Hypoglycemia is normal during the first hours of mammalian life. However, prolonged neonatal hypoglycemia would cause long-term neuronal deficits [22]. In contrast to extensively recognized hyperinsulinemic hypoglycemia, hypoinsulinemic hypoglycemia is an extremely rare condition in human. Limited cases of hypoinsulinemic hypoglycemia are usually related to impaired insulin signaling pathway. For example, a hyperactive mutation of *AKT2*, the gene required for insulin-induced translocation of GLUT4 to the plasma membrane, caused hypoinsulinemic hypoglycemia in four patients [23, 24]. On the other hand, non-islet cell tumor-induced hypoglycemia (NICTH) is caused by the secretion of incompletely processed precursors of IGF-II, which has an insulin-like hypoglycaemic activity [25]. We have shown that disruption of *Otg1* caused hypoinsulinemic hypoglycemia in mice, which implies a possible role of *Otg1* mutations in human patients. The fact that *Otg1* mutation blocked vesicle trafficking also suggests a new etiology of this rarely observed disease condition. Examine other regulators of vesicle trafficking in human patients may identify more causative mutations of hypoinsulinemic hypoglycemia in the future.

The mechanism through which *Otg1* modulates vesicle trafficking remains to be investigated. The *C. elegans* homologue of *Otg1* works as a partner of Rab-2 and Rund-1 in regulating neuronal vesicle trafficking [15]. However, mutations of the homologues of *Rab-2* (*Rab-2a* and *Rab-2b*) or *Rund-1* (*Rundc-1*) showed different phenotypes from that of *Otg1* mutants in mice [26, 27]. Unlike the *C. elegans* mutant, *Otg1^{PB/PB}* mice did not show gross behavioral defects. The observation that *Otg1^{PB/PB}* pups are capable of sucking milk suggests they may have normal neuronal functions (Additional file 3: Figure S2B). In addition, the human orthologue of *Otg1* is a tumor antigen. Thus, further studies of *Otg1* may not only shed light on the mechanisms of vesicle trafficking in mammals, but also contribute to the study of related diseases such as metabolic abnormalities or cancer.

Conclusions

Our results revealed an essential role of *Otg1* in vesicle trafficking, which is critical for peptide hormone secretion, metabolic regulation and postnatal survival in mice.

Methods

Mice

All animal experiments were performed in accordance with protocols approved by the Animal Care and Use Committee of the Institute of Developmental Biology and

Molecular Medicine (IDM), Fudan University. The *Otg1* mutant strain (H66eR12) was generated on the FVB/NJ background and maintained on 12/12-hour light/dark cycles. The *Otg1* mutation carried by H66eR12 was induced with a *piggyBac* transposon (*PB*) insertion in the eighth exon. Mapping information of the *PB* insertion in *Otg1* and the mutant genotyping protocol could be found from the PBmice database [16]. All assays were performed in a mixed population of both males and females.

Metabolic assays

Blood glucose levels were analyzed with Glucometer Elite (LifeScan). For glucose tolerant tests (GTTs), animals were fasted two hours before receiving intraperitoneal injection of 20 % glucose saline solutions (2 g glucose per kg body weight). Tail vein blood was then sampled at 0, 15, 30, 60, 90 and 120 min after injection for blood glucose tests. For insulin tolerance tests (ITTs), 2-hour fasted mice received an intraperitoneal injection of insulin (Humulin, Lilly) (0.75 U/kg body weight), then had tail vein blood glucose levels measured at 0, 15, 30, 45 and 60 min later. ELISA was performed following the manufacturer's protocol to measure serum insulin (Crystal Chem Inc.), leptin (Crystal Chem Inc.) and growth hormone (Millipore) concentrations. All samples were collected from female mice at the age of P11.

Islet culture and glucose stimulated insulin secretion (GSIS)

Pancreatic islets were isolated by collagenase perfusion in situ, digested for 28 min and then purified by single layer histopaque (Sigma). Isolated islets from different mice were mixed and cultured in RPMI 1640 medium supplemented with 11 mM glucose, 7.5 % FCS and 10 mM HEPES (Sigma). For GSIS assay, islets were washed in PBS and incubated in a 96-well plate with glucose-free Krebs–Ringer bicarbonate (KRB) medium (125 mM NaCl, 4.74 mM KCl, 1 mM CaCl₂, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 5 mM NaHCO₃, 25 mM HEPES, pH 7.4, with 0.1 % BSA) at 37 °C for 30 min, then incubated in KRB containing 3 mM or 25 mM glucose at 37 °C for 30 min with 5 islets per well. The amount of insulin released into the incubation medium in each well was assayed using ELISA (Crystal Chem Inc.). At least 5 wells were examined for each genotype with each glucose concentration.

Western blot

Protein extraction was prepared with the RIPA lysis buffer and quantified with the BCA Protein Assay Kit (Pierce). Equal amounts of samples were separated by SDS/PAGE, transferred onto PVDF membranes (Millipore) and immunoblotted following standard protocols. The antibodies used were: rabbit anti-OTG1 (Sigma

HPA018019, 1:1000), mouse anti-GAPDH (KangCheng Biotech KC-5G4, 1:10,000) rabbit anti- β -actin (Santa Cruz sc-1616-R, 1:2000), goat anti-mouse IgG-HRP (Santa Cruz sc-2005, 1:5000) and goat anti-rabbit IgG-HRP (Santa Cruz sc-2004, 1:5000).

Histology and immunohistochemistry

Frozen sections were prepared by fixing tissues overnight in 4 % paraformaldehyde, followed by cryoprotection in 30 % sucrose at 4 °C for two days and sectioning with given thickness for histological and immunofluorescence analysis. For morphological analysis, Section (5 μ m) were stained with hematoxylin and eosin to have images acquired with a Leica DMRXA2 microscope. For immunofluorescence analysis, Section (6–8 μ m) were treated following the standard protocol with following antibodies: rabbit anti-OTG1 (Sigma HPA018019, 1:1000), Alexa 488 conjugated rabbit-anti-Giantin (Covance A488-114L, 1:1000), rabbit anti-insulin (Santa Cruz sc-9168, 1:1000), goat anti-glucagon (Santa Cruz sc-7780, 1:1000), donkey anti-goat IgG-FITC (Chemicon AP180F, 1:2000), donkey anti-rabbit IgG-Cy3 (Millipore AP182C, 1:2000).

Electron microscopy

Pancreas tissues were fixed in a fresh fixative solution consisting of 2 % glutaraldehyde and 4 % paraformaldehyde, postfixed with 1 % osmium tetroxide in phosphate buffer at 4 °C and dehydrated in ascending concentrations of methanol and propyleneoxide before being embedded in Epoxy resin. Ultra-thin sections were prepared using a Reichert ultramicrotome, contrasted with uranyl acetate and lead citrate and examined under a Philips CM120 electron microscope.

Cell culture and live imaging

Rat pituitary GH3 cells were cultured at 37 °C in a humidified atmosphere containing 95 % air and 5 % CO₂. The culture medium was DMEM supplemented with 10 % fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. GH3 cells were transfected with small hairpin RNA (shRNA) constructs (Sigma-Aldrich) or the VSVG-mEmerald plasmid (modified from Addgene plasmid #31947) with Lipofectamine 2000 (Invitrogen). For growth hormone secretion assay, cells were transferred to serum free medium 48 h after transfection and incubated for 2 h before ELISA. Live cell confocal images were acquired 48 h after transfection, using spinning disk confocal scan head (CSU-X/M2 N, Yokogawa) attached to an inverted microscope (IX-81, Olympus) and an EMCCD camera (DU897BV, Andor) controlled by Micro-Manager software. Images (512 \times 512 pixels, voxel size 0.0946 μ m/pixel) were taken every 0.5 s for 400 frames. Live images were analyzed in NIH ImageJ with the MTrackJ plugin.

VSVG containing vesicles (10/cell) were randomly selected in 11 *Otg1* knockdown cells and 11 scramble shRNAs treated cells. Directionality of each vesicle was defined as its real transport distance divided by linear distance between the start and end positions.

Statistics

GSIS data were compared by two-way ANOVA analysis. All other data were compared by unpaired two-tailed Student's *t* test. Results were shown as mean \pm SEM. *P* < 0.05 was considered statistically significant.

Additional files

Additional file 1: Figure S1. *Otg1* expression is disrupted by the PB insertion. In contrast to Fig. 1c, immunofluorescence staining showed Giantin (green) but not *Otg1* (red) signals in pancreatic tissues and MEFs from *Otg1*^{PB/PB} mice.

Additional file 2: Table S1. Genotypes of new born animals.

Additional file 3: Figure S2. *Otg1* mutant mice have no severe developmental defects. (A) Alcian blue-alizarin red staining of P6 *Otg1*^{+/+} and *Otg1*^{PB/PB} mice. (B) Representative image showing P6 wild-type and *Otg1*^{PB/PB} littermates, with sucked milk in the stomach. (C) Average body weight of *Otg1*^{PB/PB} (n = 6), *Otg1*^{PB/+} (n = 15) and wild-type (n = 15) littermates at E18.5.

Additional file 4: Figure S3. *Otg1* mutation does not affect hepatocyte size. (A) H&E staining of liver sections from P11 *Otg1*^{PB/PB} and *Otg1*^{PB/+} littermates. (B) Relative hepatocytes size of P11 *Otg1*^{PB/PB} (n = 3) and *Otg1*^{PB/+} (n = 4) littermates.

Additional file 5: Video S1. GH3 cells co-transfected with VSVG-mEmerald and scramble shRNA.

Additional file 6: Video S2. GH3 cells co-transfected with VSVG-mEmerald and *Otg1* shRNA-1.

Additional file 7: Figure S4. *Otg1* knockdown blocks vesicle transportation in GH3 cells. (A) Unaltered directionality between *Otg1* knockdown (red x) and scramble shRNA treated (black crosses) GH3 cells shown in Fig. 5b. (B) Decreased standard deviation of transport speed of cells shown in Fig. 5b. ****p* < 0.005.

Abbreviations

CTCL: cutaneous T-cell lymphoma; GH: growth hormone; GHR: growth hormone receptor; GSIS: islet culture and glucose stimulated insulin secretion; GTT: glucose tolerant test; IDM: The Institute of Developmental Biology and Molecular Medicine; IPGTT: intraperitoneal glucose tolerance test; ITT: insulin tolerance test; MEF: embryonic fibroblast; NICTH: non-islet cell tumor-induced hypoglycemia; *Otg1*: oocyte testis gene 1; *PB*: *piggyBac*; shRNA: small hairpin RNA; TGN: trans-Golgi network.

Authors' contributions

GW characterized the physiological and metabolic alterations of the animals, participated in islet and cell culture experiments. RL participated in physiological and metabolic phenotyping, carried out molecular genetic experiments. YY and LC characterized vesicle trafficking alterations in GH3 cells. SD mapped the mutations and initially identified the lethality phenotype. MH and TX participated in the design of the study and helped to analyze the results. XW conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details

¹ State Key Laboratory of Genetic Engineering and National Center for International Research of Development and Disease, Institute of Developmental

Biology and Molecular Medicine, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai 200433, China. ² Howard Hughes Medical Institute, Department of Genetics, Yale University School of Medicine, New Haven, CT 06536, USA. ³ Howard Hughes Medical Institute, Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA.

Acknowledgements

We thank Dr. Lei Xue for stimulating discussions, Xiaoping Huang, Guoying Ma, Yanfeng Tan, Guicheng Wang and Yanqian Xia for technical assistance.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

All animal procedures applied in this article have been approved by the Animal Care and Use Committee of the Institute of Developmental Biology and Molecular Medicine, Fudan University, Shanghai, China.

Sources of funding

This work was supported in part by grants from Chinese Hi-tech Research and Development Project (863) [2014AA021104], Natural Science Foundation of China (NSFC) [81170789, 81570756] and Shanghai Municipal Government (15XD1500500 and 12431900100). YY has been supported by the Fudan Undergraduate Research Opportunities Program (FDUROP) and the National Top Talent Undergraduate Training Program (NTTUTP). MH and TX are Howard Hughes Medical Institute investigators.

Availability of data and materials

Not applicable, because we do not have any readily reproducible materials in the manuscript, no new software, no databases and relevant raw data are already included in the text and figures for the reviewers.

Received: 12 May 2016 Accepted: 2 June 2016

Published online: 10 June 2016

References

- Tirone TA, Brunicaudi FC. Overview of glucose regulation. *World J Surg*. 2001;25(4):461–7.
- Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. *J Clin Invest*. 2006;116(7):1767–75.
- Roder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. *Exp Mol Med*. 2016;48:e219.
- Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. *Diabetes Res Clin Pract*. 2005;67(1):3–21.
- Duvillie B, et al. Phenotypic alterations in insulin-deficient mutant mice. *Proc Natl Acad Sci USA*. 1997;94(10):5137–40.
- Vuguin PM, et al. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. *Endocrinology*. 2006;147(9):3995–4006.
- Zhou Y, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). *Proc Natl Acad Sci USA*. 1997;94(24):13215–20.
- Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. *Dev Biol*. 2001;229(1):141–62.
- Liu JL, et al. Disruption of growth hormone receptor gene causes diminished pancreatic islet size and increased insulin sensitivity in mice. *Am J Physiol Endocrinol Metab*. 2004;287(3):E405–13.
- Michael DJ, Cai H, Xiong W, Ouyang J, Chow RH. Mechanisms of peptide hormone secretion. *Trends Endocrinol Metab*. 2006;17(10):408–15.
- Park JJ, Loh YP. How peptide hormone vesicles are transported to the secretion site for exocytosis. *Mol Endocrinol*. 2008;22(12):2583–95.
- Kawai J, et al. Functional annotation of a full-length mouse cDNA collection. *Nature*. 2001;409(6821):685–90.
- Oduru S, et al. Gene discovery in the hamster: a comparative genomics approach for gene annotation by sequencing of hamster testis cDNAs. *BMC Genom*. 2003;4(1):22.
- Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmüller S. SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. *Br J Dermatol*. 2004;150(2):252–8.
- Aillon M, et al. Two Rab2 interactors regulate dense-core vesicle maturation. *Neuron*. 2014;82(1):167–80.
- PiggyBac Mutagenesis Information Center. <http://www.idmshanghai.cn/PBmice/>. Accessed 21 Nov. 2012.
- Linstedt AD, Hauri HP. Giantin, a novel conserved Golgi membrane protein containing a cytoplasmic domain of at least 350 kDa. *Mol Biol Cell*. 1993;4(7):679–93.
- Yamashita H, et al. A rat pituitary tumor cell line (GH3) expresses type I and type II receptors and other cell surface binding protein(s) for transforming growth factor-beta. *J Biol Chem*. 1995;270(2):770–4.
- Toomre D, Keller P, White J, Olivo JC, Simons K. Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells. *J Cell Sci*. 1999;112(Pt 1):21–33.
- Gillingham AK, Munro S. Finding the Golgi: golgin coiled-coil proteins show the way. *Trends Cell Biol*. 2016;26(6):399–408.
- Witkos TM, Lowe M. The Golgin Family of Coiled-Coil Tethering Proteins. *Front Cell Dev Biol*. 2016;11(3):86.
- Adamkin DH. Neonatal hypoglycemia. *Curr Opin Pediatr*. 2016;28(2):150–5.
- Arya VB, et al. Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia. *J Clin Endocrinol Metab*. 2014;99(2):391–4.
- Hussain K, et al. An activating mutation of AKT2 and human hypoglycemia. *Science*. 2011;334(6055):474.
- Dutta P, et al. Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature. *Endocrinol Diabetes Metab Case Rep*. 2013;2013:130046.
- Zambrowicz BP, et al. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. *Proc Natl Acad Sci USA*. 2003;100(24):14109–14.
- (MGP) MGlatWTSIMGP (2011) Obtaining and loading phenotype annotations from the Wellcome Trust Sanger Institute (WTSI) Mouse Resources Portal. *Database Release*.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

